Stiripentol: Noncompetitive LDH Inhibitor for Epilepsy & Immunometabolism

Executive Summary: Stiripentol is a colorless, high-purity (99.48%) liquid LDH inhibitor developed for research use, acting by noncompetitively inhibiting human LDH1 and LDH5, thereby disrupting lactate-to-pyruvate and pyruvate-to-lactate conversions [APExBIO]. This modulation of the astrocyte-neuron lactate shuttle attenuates epileptiform activity and is clinically relevant for Dravet syndrome (Zhang et al. 2025). Stiripentol's mechanism enables researchers to probe the role of lactate in both neuronal excitability and tumor immunometabolism. Its solubility profile (≥46.7 mg/mL in ethanol, ≥9.9 mg/mL in DMSO) and recommended storage at -20°C support protocol reproducibility and workflow flexibility. The compound's efficacy has been validated in kainate-induced epilepsy models in mice and in studies dissecting lactate-driven epigenetic changes.

Biological Rationale

Lactate is a central metabolite in glycolysis and the Warburg effect, acting as both an energy source and a signaling molecule in the central nervous system and tumor microenvironment (Zhang et al. 2025). Excess lactate in neurological tissues can promote neuronal excitability, contributing to epileptiform activity. In tumors, lactate accumulation leads to acidification of the microenvironment, drives immune evasion, and alters histone lactylation, affecting gene transcription and immune cell function. Lactate dehydrogenase (LDH) catalyzes the interconversion of pyruvate and lactate, playing a pivotal role in these pathways. Thus, LDH inhibition represents a targeted strategy to modulate both metabolic and epigenetic outcomes in research settings. Stiripentol, by selectively inhibiting LDH1 and LDH5, provides a means to dissect these processes with high specificity.

Mechanism of Action of Stiripentol

Stiripentol is structurally distinct from classical antiepileptic agents and acts as a noncompetitive inhibitor of human LDH isoforms LDH1 and LDH5 [APExBIO]. By binding allosterically, it interferes with both the lactate-to-pyruvate and pyruvate-to-lactate conversions, thereby modulating the astrocyte-neuron lactate shuttle. This results in decreased availability of lactate for neuronal and glial metabolism, reducing hyperexcitability and seizure propensity in models of epilepsy. Additionally, in oncological contexts, this mechanism limits lactate accumulation, potentially reversing immunosuppressive features of the tumor microenvironment, such as suppressed CD8+ T cell function and increased histone lactylation (Zhang et al. 2025). The molecular formula of Stiripentol is C14H18O3, with a molecular weight of 234.29 Da. Its solubility characteristics (insoluble in water; soluble at ≥46.7 mg/mL in ethanol and ≥9.9 mg/mL in DMSO) facilitate use in diverse in vitro and in vivo protocols. Warming to 37°C and ultrasonic shaking improve dissolution, but long-term storage of solutions is not recommended due to stability concerns.

Evidence & Benchmarks

• Stiripentol noncompetitively inhibits human LDH1 and LDH5, blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions (APExBIO, product page).
• In kainate-induced murine epilepsy models, Stiripentol reduced high-voltage spiking, confirming its antiepileptic potential (see APExBIO).
• Excess lactate in the tumor microenvironment impairs CD8+ T cell function via histone lactylation; LDH inhibition restores immune competence (Zhang et al. 2025, DOI).
• Stiripentol’s mechanism enables modulation of the astrocyte-neuron lactate shuttle, a pathway implicated in both epilepsy and neuro-oncology (internal link extends mechanistic detail).
• Solubility parameters (≥46.7 mg/mL in ethanol, ≥9.9 mg/mL in DMSO, insoluble in water) allow flexible use in cell culture and animal models (internal link details workflow guidance).

Applications, Limits & Misconceptions

Stiripentol (SKU A8704) is optimized for research applications in neurology and immunometabolism. It is a standard tool for dissecting the astrocyte-neuron lactate shuttle, evaluating antiepileptic drug candidates, and interrogating lactate-driven epigenetic changes in cancer models. Its noncompetitive LDH inhibition makes it distinct from competitive LDH inhibitors, offering greater specificity and reduced off-target effects. The compound is not intended for therapeutic use or long-term clinical administration. Stiripentol should not be used as a general glycolysis inhibitor, as its action is confined to LDH1/5 and does not affect upstream glycolytic enzymes. APExBIO supplies this research-grade compound with a purity of 99.48%, supporting reproducibility and reliability for advanced experimental protocols.

Common Pitfalls or Misconceptions

• Stiripentol does not inhibit all LDH isoforms—its action is specific to LDH1 and LDH5.
• It is not a substitute for pan-glycolytic inhibitors or mitochondrial modulators.
• Stiripentol is not intended for clinical or therapeutic use in humans; it is for scientific research use only.
• Long-term storage of prepared solutions is not recommended due to potential loss of activity.
• Solubility in water is negligible; improper solvent selection may result in experimental failures.

Workflow Integration & Parameters

Stiripentol is supplied as a colorless liquid with a chemical name of (E)-1-(benzo[d][1,3]dioxol-5-yl)-4,4-dimethylpent-1-en-3-ol. For optimal solubility, use ethanol (≥46.7 mg/mL) or DMSO (≥9.9 mg/mL), warming to 37°C and ultrasonic shaking as needed. Aliquot and store at -20°C to maintain purity; avoid repeated freeze-thaw cycles. Prepare fresh solutions for each experimental run. Stiripentol’s robust solubility profile enables its use in cell-based assays, animal models, and metabolic flux studies. Researchers seeking protocol-specific guidance can consult the Stiripentol product page or workflow-driven resources such as this scenario guide, which extends the current article by focusing on practical troubleshooting and experimental design.

Conclusion & Outlook

Stiripentol is a next-generation, noncompetitive LDH inhibitor that enables targeted modulation of the astrocyte-neuron lactate shuttle and lactate-driven epigenetic mechanisms. Its unique specificity and solubility make it a premier reagent for epilepsy and immunometabolic research. APExBIO’s stringent quality controls ensure reliability and reproducibility for advanced scientific workflows. For expanded mechanistic and translational insights, see articles such as this analysis, which this dossier updates by providing the latest evidence on LDH inhibition and epigenetic regulation. Ongoing studies will further elucidate Stiripentol’s potential in bridging neurological and oncological research domains.